Sign In
Buy SNY
$42.37
-0.430 (-1.00%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Sunday, 27'th Jul 2025
NEW YORK , July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Da
Press Release: Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
01:00am, Friday, 25'th Jul 2025
Sanofi's Sarclisa approved in the EU for the treatment of transplant-eligible newly diagnosed multiple myeloma
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Tuesday, 22'nd Jul 2025
NEW YORK , July 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Dan
France's Sanofi to acquire biotech firm Vicebio for $1.15 bln
01:43am, Tuesday, 22'nd Jul 2025
French pharmaceuticals company Sanofi said on Tuesday it agreed to acquire British private biotechnology firm Vicebio for a total of $1.15 billion, in a bid to expand its respiratory vaccines portfoli
Press Release: Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline
01:30am, Tuesday, 22'nd Jul 2025
Sanofi to acquire Vicebio, expanding respiratory vaccines pipeline Paris, July 22, 2025. Sanofi today announces it has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately hel
Press Release: Sanofi completes acquisition of Blueprint Medicines
01:00am, Friday, 18'th Jul 2025
Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfol
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Thursday, 17'th Jul 2025
NEW YORK , July 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Dan
Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag
12:56pm, Wednesday, 16'th Jul 2025
SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.
Thermo Fisher acquires Sanofi's New Jersey manufacturing site
09:35am, Wednesday, 16'th Jul 2025
Thermo Fisher said on Wednesday it will buy Sanofi's manufacturing site in Ridgefield, New Jersey, to produce critical medicines for the French drugmaker.
Thermo Fisher Scientific and Sanofi Expand Strategic Partnership to Enable Additional U.S. Drug Product Manufacturing
08:00am, Wednesday, 16'th Jul 2025
WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced an expansion of their strategic partnership with Sanofi to enable additi
Press Release: Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
01:00am, Wednesday, 16'th Jul 2025
Sanofi's SAR446597 earns fast track designation in the US for geographic atrophy due to age-related macular degeneration
Sanofi: A Solid EU Contrarian Play
05:28am, Tuesday, 15'th Jul 2025
Sanofi is a high-quality, undervalued pharma giant trading near 10x P/E, offering a compelling contrarian opportunity despite recent price declines. Strong cash flow, AA credit rating, and a 4.7% yiel
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of V
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
10:00am, Saturday, 12'th Jul 2025
NEW YORK , July 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Danie
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY
04:07pm, Monday, 07'th Jul 2025
NEW YORK , July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY). Such investors are advised to contact Daniel
